Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Solitary Fibrous Tumors: early-phase trial registry

1 of 1 indexed Solitary Fibrous Tumors trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Solitary Fibrous Tumors: 1 US clinical trial tracked, 1 recruiting.

Solitary Fibrous Tumors is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Epkin, running 1 of these trials.

Enrollment posture brief

Registry condition solitary-fibrous-tumors

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Solitary Fibrous Tumors (thi…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Solitary Fibrous Tumors

Solitary Fibrous Tumors lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Solitary Fibrous Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Solitary Fibrous Tumors is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Epkin 1 trials

Named interventions

Most-linked intervention names on Solitary Fibrous Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fed Other
1 trials
OKN4395 Drug
1 trials
H2 Receptor Antagonist Drug
1 trials
Pembrolizumab Combination
1 trials
Fasting Other
1 trials

US sites by state

Facility locations filed on Solitary Fibrous Tumors trials. A trial with sites in several states counts in each.

Texas 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Solitary Fibrous Tumors page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Solitary Fibrous Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Epkin sponsors the most Solitary Fibrous Tumors trials on record, review their full trial history before evaluating a specific study. See Epkin's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solitary Fibrous Tumors condition card totals 1 registered trials; most-linked intervention Fed; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.